Xenograft-directed Personalized Therapy for a Patient with Post-transplant Relapse of ALL

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2016 May 17

PMID 27183096

Citations 4

Authors

T N Trahair

R B Lock

R Sutton

K C S Sia

K Evans

J RICHMOND

T Law

N C Venn

J A Irving

S Moore

E Nievergall

P Dang

S L Heatley

D L White

T Revesz

Affiliations

Soon will be listed here.

Citing Articles

The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care.

Wakefield C, Doolan E, Fardell J, Signorelli C, Quinn V, Tucker K EBioMedicine. 2018; 37:205-213.

PMID: 30385234 PMC: 6286267. DOI: 10.1016/j.ebiom.2018.10.060.

Protocol for the avatar acceptability study: a multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New Zealand.

Wakefield C, Doolan E, Fardell J, Signorelli C, Quinn V, Tucker K BMJ Open. 2018; 8(8):e024064.

PMID: 30093523 PMC: 6089310. DOI: 10.1136/bmjopen-2018-024064.

Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Jones L, Richmond J, Evans K, Carol H, Jing D, Kurmasheva R Clin Cancer Res. 2017; 23(14):3744-3755.

PMID: 28119366 PMC: 5943062. DOI: 10.1158/1078-0432.CCR-16-2392.

A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.

El-Hoss J, Jing D, Evans K, Toscan C, Xie J, Lee H Oncotarget. 2016; 7(37):60475-60490.

PMID: 27528024 PMC: 5312397. DOI: 10.18632/oncotarget.11125.

References

Carol H, Szymanska B, Evans K, Boehm I, Houghton P, Smith M . The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res. 2013; 19(7):1795-805. PMC: 3618498. DOI: 10.1158/1078-0432.CCR-12-3613. View

Eapen M, Giralt S, Horowitz M, Klein J, Wagner J, Zhang M . Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004; 34(8):721-7. DOI: 10.1038/sj.bmt.1704645. View

Szymanska B, Wilczynska-Kalak U, Kang M, Liem N, Carol H, Boehm I . Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One. 2012; 7(3):e33894. PMC: 3315513. DOI: 10.1371/journal.pone.0033894. View

Case M, Matheson E, Minto L, Hassan R, Harrison C, Bown N . Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008; 68(16):6803-9. DOI: 10.1158/0008-5472.CAN-08-0101. View

Hijiya N, Stewart C, Zhou Y, Campana D, Coustan-Smith E, Rivera G . Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer. 2008; 112(9):1983-91. DOI: 10.1002/cncr.23395. View

Bader P, Kreyenberg H, Henze G, Eckert C, Reising M, Willasch A . Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2008; 27(3):377-84. DOI: 10.1200/JCO.2008.17.6065. View

Schmitz M, Breithaupt P, Scheidegger N, Cario G, Bonapace L, Meissner B . Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood. 2011; 118(7):1854-64. DOI: 10.1182/blood-2010-11-320309. View

Weston B, Hayden M, Roberts K, Bowyer S, Hsu J, Fedoriw G . Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25):e413-6. DOI: 10.1200/JCO.2012.47.6770. View

Roberts K, Li Y, Payne-Turner D, Harvey R, Yang Y, Pei D . Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11):1005-15. PMC: 4191900. DOI: 10.1056/NEJMoa1403088. View

10.

Clappier E, Gerby B, Sigaux F, Delord M, Touzri F, Hernandez L . Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011; 208(4):653-61. PMC: 3135355. DOI: 10.1084/jem.20110105. View

11.

Messinger Y, Gaynon P, Sposto R, van der Giessen J, Eckroth E, Malvar J . Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012; 120(2):285-90. DOI: 10.1182/blood-2012-04-418640. View

12.

Houghton P, Morton C, Kolb E, Lock R, Carol H, Reynolds C . Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2007; 50(1):37-45. DOI: 10.1002/pbc.21214. View

13.

Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman A . Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010; 376(9757):2009-17. PMC: 3010035. DOI: 10.1016/S0140-6736(10)62002-8. View

14.

Carol H, Houghton P, Morton C, Kolb E, Gorlick R, Reynolds C . Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009; 54(5):707-15. PMC: 2923808. DOI: 10.1002/pbc.22352. View

15.

Liem N, Papa R, Milross C, Schmid M, Tajbakhsh M, Choi S . Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004; 103(10):3905-14. DOI: 10.1182/blood-2003-08-2911. View